Literature DB >> 22071661

Are Th17 cells in the gut pathogenic or protective?

A Symons1, A L Budelsky, J E Towne.   

Abstract

Th17 cells are abundant in multiple chronic inflammatory and autoimmune diseases. Clinical trials with antibodies to interleukin (IL)-17A, one of the Th17-cell signature cytokines, have recently reported therapeutic benefit in multiple patient populations; however, in Crohn's disease the role of Th17 cells and IL-17A appears to be more complicated. The development of different subsets of Th17 cells and their relative pathogenic activities with a focus on the gut environment will be discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22071661     DOI: 10.1038/mi.2011.51

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  12 in total

1.  Assessing the development of murine plasmacytoid dendritic cells in Peyer's patches using adoptive transfer of hematopoietic progenitors.

Authors:  Haiyan S Li; Stephanie S Watowich
Journal:  J Vis Exp       Date:  2014-03-17       Impact factor: 1.355

Review 2.  IL-17 and limits of success.

Authors:  Zahra Omidian; Rizwan Ahmed; Adebola Giwa; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cell Immunol       Date:  2018-09-17       Impact factor: 4.868

Review 3.  Microbiota-specific Th17 Cells: Yin and Yang in Regulation of Inflammatory Bowel Disease.

Authors:  Wei Wu; Feidi Chen; Zhanju Liu; Yingzi Cong
Journal:  Inflamm Bowel Dis       Date:  2016-06       Impact factor: 5.325

Review 4.  Targeting IL-17 and TH17 cells in chronic inflammation.

Authors:  Pierre Miossec; Jay K Kolls
Journal:  Nat Rev Drug Discov       Date:  2012-10       Impact factor: 84.694

Review 5.  Pathogenesis of NEC: Role of the innate and adaptive immune response.

Authors:  Timothy L Denning; Amina M Bhatia; Andrea F Kane; Ravi M Patel; Patricia W Denning
Journal:  Semin Perinatol       Date:  2016-12-09       Impact factor: 3.300

6.  Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda.

Authors:  Lee A Denson; Millie D Long; Dermot P B McGovern; Subra Kugathasan; Gary D Wu; Vincent B Young; Theresa T Pizarro; Edwin F de Zoeten; Thaddeus S Stappenbeck; Scott E Plevy; Clara Abraham; Asma Nusrat; Christian Jobin; Declan F McCole; Corey A Siegel; Peter D R Higgins; Hans H Herfarth; Jeffrey Hyams; William J Sandborn; Edward V Loftus; Michael D Kappelman; James D Lewis; Charles A Parkos; R Balfour Sartor
Journal:  Inflamm Bowel Dis       Date:  2013 Mar-Apr       Impact factor: 5.325

7.  The MicroRNA-183-96-182 Cluster Promotes T Helper 17 Cell Pathogenicity by Negatively Regulating Transcription Factor Foxo1 Expression.

Authors:  Kenji Ichiyama; Alicia Gonzalez-Martin; Byung-Seok Kim; Hyun Yong Jin; Wei Jin; Wei Xu; Mohsen Sabouri-Ghomi; Shunbin Xu; Pan Zheng; Changchun Xiao; Chen Dong
Journal:  Immunity       Date:  2016-06-21       Impact factor: 31.745

Review 8.  Clinical consequences of targeting IL-17 and TH17 in autoimmune and allergic disorders.

Authors:  Keven M Robinson; Michelle L Manni; Partha S Biswas; John F Alcorn
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

9.  TIR-domain-containing adapter-inducing interferon-β (TRIF) regulates Th17-mediated intestinal immunopathology in colitis.

Authors:  S Kanagavelu; C Flores; J M Termini; R Riveron; L Romero; K Chung; J Ruiz; J Hyun; X Yuan; J Dagvadorj; M Fukata
Journal:  Mucosal Immunol       Date:  2014-07-30       Impact factor: 7.313

10.  Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway.

Authors:  J Park; M Kim; S G Kang; A H Jannasch; B Cooper; J Patterson; C H Kim
Journal:  Mucosal Immunol       Date:  2014-06-11       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.